223. 一次性膜性増殖性糸球体腎炎 Disease details / Clinical trials / Drug dev / DR info /

Abatacept
   Bristol-Myers Squibb
      2007   Phase 2/Phase 3   NCT00430677   Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2014   Phase 3   EUCTR2012-000714-11-ES   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;India;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2013   Phase 3   EUCTR2012-000714-11-RO   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;India;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2013   Phase 3   EUCTR2012-000714-11-IT   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;India;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2013   Phase 3   EUCTR2012-000714-11-CZ   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2008   Phase 2;Phase 3   EUCTR2005-004575-37-GB   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-FR   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-BE   Belgium;France;United Kingdom
   Department of Cardiorenal Medicine, Yokohama City University School of Medicine
      2011   Phase 3   JPRN-UMIN000006080   Japan
Abetimus sodium
   La Jolla Pharmaceutical Company
      2001   Phase 3   NCT00035308   Austria;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
Acei
   Christian Medical College, Vellore, India
      2025   Phase 4   NCT06676384   India
ACH-0144471
   Achillion Pharmaceuticals, Inc.
      2019   Phase 2   EUCTR2017-002674-39-NL   Australia;Belgium;Italy;Netherlands;United States
      2018   Phase 2   EUCTR2017-002674-39-BE   Australia;Belgium;Italy;Netherlands;United States
      2018   Phase 2   EUCTR2017-000663-33-GB   Canada;United Kingdom;United States
      2018   Phase 2   EUCTR2016-003525-42-NL   Australia;Belgium;Netherlands
      -   Phase 2   EUCTR2016-003525-42-BE   Australia;Belgium;Netherlands
   Alexion Pharmaceuticals
      2017   Phase 2   NCT03124368   Australia;Belgium;Netherlands
ACH-0144471 compresse
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States
ACH0144471 compresse
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States
ACT-HIB
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States
ACT-HIB polvere E solvente PER soluzione iniettabile IN siringa preriempita 0,5 ML
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004589-21-IT   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
Acthar GEL
   Ohio State University
      2013   Phase 4   NCT01926054   United States
Acthar GEL 80 UNT/ML injectable solution
   NephroNet, Inc.
      2019   Phase 4   NCT05546047   United States
Acthib - polvere E solvente PER soluzione iniettabile 1 flaconcino polve
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2017-000889-29-IT   France;Germany;Italy;Spain;United Kingdom;United States
Adrenocorticotrophic hormone acth
   University Health Network, Toronto
      2010   Phase 1/Phase 2   NCT01093157   Canada
ADX-038
   ADARx Pharmaceuticals, Inc.
      2026   Phase 2   NCT07522099   China
ADX-038 dose level 1
   ADARx Pharmaceuticals, Inc.
      2025   Phase 2   NCT06989359   Australia;Hong Kong;South Korea;Spain;United Kingdom;United States
ADX-038 dose level 2
   ADARx Pharmaceuticals, Inc.
      2025   Phase 2   NCT06989359   Australia;Hong Kong;South Korea;Spain;United Kingdom;United States
AKF2328
   Radboudumc, Amalia Children’s Hospital, Department of Pediatrics
      2016   Phase 4   EUCTR2016-002430-76-NL   Belgium;Germany;Netherlands
ALE.F02
   Alentis Therapeutics AG
      2023   Phase 2   NCT06047171   Czechia;Denmark;France;Germany;Italy;Spain;Sweden;Switzerland;Turkey (Türkiye);United Kingdom
Alendronate sodium
   Kakogawa central city hospital
      2016   Phase 3   JPRN-UMIN000022873   Japan
Alfacalcidol
   Aarhus University hospital
      2017   Phase 4   EUCTR2017-001206-16-DK   Denmark
Aliskiren
   Columbia University
      2009   Phase 4   NCT01129557   United States
   Kagawa University
      2010   Phase 4   NCT01184599   Japan
   Region Skane
      2020   Phase 2   NCT04183101   Sweden
Aliskiren generic
   Skåne University Hospital
      2019   Phase 2   EUCTR2019-001440-22-SE   Sweden
AMG 811
   Amgen
      2009   Phase 1   NCT00818948   France;Hong Kong;Malaysia;Mexico;Singapore;United States
ANTI-CD20 antibodies
   University of Turin, Italy
      2022   Phase 4   NCT06680349   Italy
Apixaban
   Aarhus University Hospital, Henrik Birn
      2020   Phase 1;Phase 2   EUCTR2019-001212-29-DK   Denmark
APL-2
   APELLIS PHARMACEUTCIALS, INC.
      2022   Phase 3   EUCTR2020-003767-25-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Apellis Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-003767-25-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-NL   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-FR   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-AT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2020   Phase 2   EUCTR2020-002637-15-GB   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2018   Phase 2   NCT03453619   United States
      -   Phase 3   EUCTR2022-002833-33-FR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2022-002833-33-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2020-003767-25-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
ARB
   Christian Medical College, Vellore, India
      2025   Phase 4   NCT06676384   India
ARO-C3
   Arrowhead Pharmaceuticals
      2022   Phase 1/Phase 2   NCT05083364   Australia;Georgia;Germany;New Zealand;South Korea;Spain;Thailand;United Kingdom
Arzerra
   IRCCS Istituto Giannina Gaslini
      -   Phase 2   EUCTR2018-001042-33-IT   Italy
Aspaveli
   Apellis Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-003767-25-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-NL   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-AT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2022-002833-33-FR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2022-002833-33-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom;United States
ATG-F
   Centre Hospitalier Universitaire de Saint Etienne
      2011   Phase 4   NCT02523768   France
Avacopan
   Amgen
      2017   Phase 2   NCT03301467   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
   ChemoCentryx, Inc.
      2018   Phase 2   EUCTR2017-001821-42-NL   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-001821-42-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-001821-42-GB   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-001821-42-BE   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-IE   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-FR   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-ES   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-DK   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-DE   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
Azathioprine
   Children's Hospital Affiliated to Chongqing Medical University
      2020   -   ChiCTR2000034214   China
   Department of Rheumatology, Internal Medicine III, Medical University of Vienna
      2006   -   EUCTR2005-004067-30-NL   Austria;Germany;Netherlands
      2006   -   EUCTR2005-004067-30-DE   Austria;Germany;Netherlands
      2006   -   EUCTR2005-004067-30-AT   Austria;Germany;Netherlands
   Frédéric A. Houssiau, MD, PhD
      2001   Phase 3   NCT00204022   Belgium
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany
   RenJi Hospital
      2010   -   NCT01172002   China
BCX9930 hydrochloride
   BIOCRYST PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-005855-19-IT   France;Germany;Hungary;Italy;Spain;United Kingdom
   BioCryst Pharmaceuticals Inc
      2022   Phase 2   EUCTR2020-005855-19-HU   France;Germany;Hungary;Italy;Romania;Spain;United Kingdom
      2021   Phase 2   EUCTR2020-005855-19-ES   France;Germany;Hungary;Italy;Spain;United Kingdom
Belimumab
   GlaxoSmithKline
      2012   Phase 2   NCT01610492   United Kingdom
Belimumab 10 MG
   GlaxoSmithKline
      2013   Phase 2   NCT01762852   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
Bexsero
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States
Bexsero - sospensione iniettabile - USO intramuscolare - siringa preriempita (vetro) - 0.5ML - 1 siringa preriempita CON AGO
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2017-000889-29-IT   France;Germany;Italy;Spain;United Kingdom;United States
Bexsero meningococcal group B vaccine FOR injection IN PRE-filled syringe
   APELLIS PHARMACEUTCIALS, INC.
      2022   Phase 3   EUCTR2020-003767-25-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
Bexsero – sospensione iniettabile – siringa preriempita
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004589-21-IT   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
BG9588
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      1999   Phase 2   NCT00001789   United States
Blood collection
   Centre Hospitalier Universitaire de Besancon
      2023   -   NCT05791162   France
Blood sample
   University Hospital, Limoges
      2019   -   NCT04092491   France
BMS-188667
   Bristol-Myers Squibb International Corporation
      2014   Phase 3   EUCTR2012-000714-11-ES   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;India;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2013   Phase 3   EUCTR2012-000714-11-RO   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;India;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2013   Phase 3   EUCTR2012-000714-11-IT   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;India;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2013   Phase 3   EUCTR2012-000714-11-CZ   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2008   Phase 2;Phase 3   EUCTR2005-004575-37-GB   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-FR   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-BE   Belgium;France;United Kingdom
Bortezomib
   Peking University First Hospital
      2023   -   ChiCTR2500102928   China
   Ruijin Hospital
      2022   -   NCT05383547   China
Brivekimig
   Sanofi
      2024   Phase 2   NCT06500702   Argentina;Australia;Brazil;Canada;Chile;China;Czechia;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Slovakia;Spain;Taiwan;Turkey (Türkiye);United Kingdom;United States
Calcitriol
   Peking University First Hospital
      2009   Phase 4   NCT00862693   China
CCX168
   ChemoCentryx, Inc.
      2018   Phase 2   EUCTR2017-001821-42-NL   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-001821-42-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-001821-42-GB   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-001821-42-BE   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-IE   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-FR   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-ES   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-DK   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-DE   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2015   Phase 2   EUCTR2014-003402-33-SE   Belgium;Sweden;United States
      2015   Phase 2   EUCTR2014-003402-33-BE   Belgium;Sweden;United States
CD19-targeted inkt cell injection
   Grit Biotechnology
      2026   Early Phase 1   NCT07389499   China
CDX-1135
   Celldex Therapeutics
      2013   Phase 1   NCT01791686   United States
Cellcept
   Bristol-Myers Squibb International Corporation
      2013   Phase 3   EUCTR2012-000714-11-RO   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;India;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2013   Phase 3   EUCTR2012-000714-11-IT   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;India;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2008   Phase 2;Phase 3   EUCTR2005-004575-37-GB   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-FR   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-BE   Belgium;France;United Kingdom
   Imperial College Healthcare NHS trust
      2008   Phase 4   EUCTR2008-001009-41-GB   United Kingdom
   University of Washington
      2006   Phase 2   NCT00446459   United States
Cemdisiran
   Alnylam Pharmaceuticals
      2019   Phase 2   NCT03841448   Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Clexane
   IIT : University Hospital - Medical Clinic II (Director: Prof. Dr. med. J. Floege - Sponsor)
      2006   -   EUCTR2005-002989-11-DE   Germany
Corticosteroid
   Fondazione Schena
      2023   Phase 4   NCT04662723   Italy
Corticosteroids
   Bristol-Myers Squibb
      2007   Phase 2/Phase 3   NCT00430677   Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States
   National Taiwan University Hospital
      2006   Phase 3   NCT00354198   Taiwan
CPV-104
   eleva GmbH
      2025   Phase 1   NCT07483827   Austria;Belgium;Czechia;France;Greece;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden
CTLA4IG
   Bristol-Myers Squibb International Corporation
      2008   Phase 2;Phase 3   EUCTR2005-004575-37-GB   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-FR   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-BE   Belgium;France;United Kingdom
Cyclophosphamid
   Alentis Therapeutics AG
      2023   Phase 2   NCT06047171   Czechia;Denmark;France;Germany;Italy;Spain;Sweden;Switzerland;Turkey (Türkiye);United Kingdom
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany
Cyclophosphamide
   Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
      2012   Phase 3   NCT03018535   Italy
   Children's Hospital Affiliated to Chongqing Medical University
      2023   -   ChiCTR2300067726   China
      2020   -   ChiCTR2000034214   China
   Peking University First Hospital
      2023   -   ChiCTR2500102928   China
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany
Cyclophosphamide and steroids
   Radboud University
      1997   Phase 3   NCT00135954   Netherlands
Cyclosporin
   Assiut University
      2017   Phase 3   NCT03180723   -
Cyclosporin, LOW dose steroid
   Kyungpook National University Hospital
      2011   Phase 3   NCT01282073   South Korea
Cyclosporine
   Oulu University Hospital
      2000   Phase 4   NCT00425724   Finland
Dalteparin
   Aarhus University Hospital, Henrik Birn
      2020   Phase 1;Phase 2   EUCTR2019-001212-29-DK   Denmark
Danicopan
   Alexion
      2018   Phase 2   NCT03459443   Australia;Belgium;Italy;Netherlands;United States
   Alexion Pharmaceuticals
      2018   Phase 2   NCT03369236   United Kingdom;United States
Daratumumab
   Helsinki University Central Hospital
      2024   Phase 2   NCT06889948   Finland
   Mayo Clinic
      2023   Phase 2   NCT05654506   United States
Denosumab
   Kakogawa central city hospital
      2016   Phase 3   JPRN-UMIN000022873   Japan
   Showa University School of Medicine
      2015   -   JPRN-UMIN000019574   Japan
Depomedrol
   ISTITUTO GIANNINA GASLINI
      2008   -   EUCTR2007-007793-29-IT   Italy
Desmopressin
   Medical University of Bialystok
      2022   Phase 3   EUCTR2021-006647-99-PL   Poland
Dexamethasone
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 2   NCT00004990   United States
   Peking University First Hospital
      2023   -   ChiCTR2500102928   China
Dfpp&CTX
   Zhi-Hong Liu, M.D.
      2014   -   NCT02294344   China
Eculizumab
   Columbia University
      2010   Phase 1   NCT01221181   United States
   IRCCS- Mario Negri Institute
      2014   Phase 2   EUCTR2013-003826-10-IT   Italy
   Mario Negri Institute for Pharmacological Research
      2014   Phase 2   NCT02093533   Italy
   The First Affiliated Hospital, Zhejiang University School of Medicine
      2026   Phase 4   ChiCTR2600122042   China
      2026   -   ChiCTR2600116985   China
Elbasvir/grazoprevir
   University of Florence
      2018   -   NCT03433326   -
Eliquis
   Aarhus University Hospital, Henrik Birn
      2020   Phase 1;Phase 2   EUCTR2019-001212-29-DK   Denmark
Empagliflozin 25 MG
   Kasr El Aini Hospital
      2020   Phase 3   NCT05283057   Egypt
Enalapril
   National Center for Research Resources (NCRR)
      2000   -   NCT00006137   -
   Region Skane
      2020   Phase 2   NCT04183101   Sweden
Enalapril generic
   Skåne University Hospital
      2019   Phase 2   EUCTR2019-001440-22-SE   Sweden
Endoxan baxter*50CPR RIV 50MG
   AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
      2012   -   EUCTR2011-006115-59-IT   Italy
Enoxaparin-natrium
   IIT : University Hospital - Medical Clinic II (Director: Prof. Dr. med. J. Floege - Sponsor)
      2006   -   EUCTR2005-002989-11-DE   Germany
Finerenone
   Alexandria University
      2025   Phase 2   NCT06835322   Egypt
Forxiga
   Centre Hospitalier Universitaire de Nice
      2025   Phase 2   NCT07096986   France
Fragmin
   Aarhus University Hospital, Henrik Birn
      2020   Phase 1;Phase 2   EUCTR2019-001212-29-DK   Denmark
Frexalimab
   Sanofi
      2024   Phase 2   NCT06500702   Argentina;Australia;Brazil;Canada;Chile;China;Czechia;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Slovakia;Spain;Taiwan;Turkey (Türkiye);United Kingdom;United States
GFB-887
   Goldfinch Bio, Inc.
      2021   Phase 2   NCT04950114   United States
      2020   Phase 2   NCT04387448   United States
Globulines antilymphocytaires fresenius
   CHU Saint-Etienne
      2010   Phase 4   EUCTR2009-018189-36-FR   France;Spain
Glucocorticoid
   Alentis Therapeutics AG
      2023   Phase 2   NCT06047171   Czechia;Denmark;France;Germany;Italy;Spain;Sweden;Switzerland;Turkey (Türkiye);United Kingdom
   Children's Hospital Affiliated to Chongqing Medical University
      2023   -   ChiCTR2300067726   China
      2020   -   ChiCTR2000034214   China
GUT-directed budesonide and SOC
   Christian Medical College, Vellore, India
      2025   Phase 4   NCT06676384   India
Hiberix - polvere E solvente PER soluzione iniettabile PER USO intramuscolare 1 flaconcino DI polvere + 1 siringa preriempita DI solvente DA 0.5 ML
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004589-21-IT   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
HRS-5965
   Chengdu Suncadia Medicine Co., Ltd.
      2022   Phase 1   NCT05505955   China
Huaiqihuang granules
   The First Affiliated Hospital of Dalian Medical University
      2020   Phase 4   NCT04263922   China
   the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100053690   China
Hydroxychloroquine and SOC
   Christian Medical College, Vellore, India
      2025   Phase 4   NCT06676384   India
Immunosuppressive agents
   Alentis Therapeutics AG
      2023   Phase 2   NCT06047171   Czechia;Denmark;France;Germany;Italy;Spain;Sweden;Switzerland;Turkey (Türkiye);United Kingdom
Infliximab
   Department of Rheumatology, Internal Medicine III, Medical University of Vienna
      2006   -   EUCTR2005-004067-30-NL   Austria;Germany;Netherlands
      2006   -   EUCTR2005-004067-30-DE   Austria;Germany;Netherlands
      2006   -   EUCTR2005-004067-30-AT   Austria;Germany;Netherlands
   Medical University of Vienna
      2006   Phase 2/Phase 3   NCT00368264   Austria;Germany;Netherlands
Inhibace/cozaar
   Peking University
      2006   -   NCT00378443   -
Injection OF MSC303
   Shanghai Changzheng Hospital
      2025   Phase 1/Phase 2   NCT07000292   China
Intravenous (I.V.) methylprednisolone 1000 MG, total 9
   Radboud University
      2002   Phase 2/Phase 3   NCT00135967   Netherlands
Invirase
   OSPEDALE POLICLINICO S. MATTEO
      2009   -   EUCTR2009-013484-19-IT   Italy
Iptacopan
   Maruyama Hideki
      2024   Phase 3   JPRN-jRCT2031230365   Canada;Japan;Turkey;US;Vietnam
      2022   Phase 3   JPRN-jRCT2041220097   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;UK;US
   Novartis Farmacéutica S.A.
      -   Phase 3   EUCTR2020-004589-21-ES   Argentina;Belgium;Brazil;Canada;China;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Pharma AG
      2023   Phase 3   EUCTR2018-004253-24-CZ   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004589-21-NL   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004589-21-GR   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004589-21-FR   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004589-21-CZ   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2020-004589-21-BE   Argentina;Belgium;Brazil;Canada;China;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2018-004253-24-DE   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Türkiye;United Kingdom;United States
   Novartis Pharmaceuticals
      2026   -   NCT07331259   -
      2025   Phase 2   NCT06797518   Argentina;Israel;Malaysia;Saudi Arabia;United States
      2023   Phase 3   NCT05755386   Argentina;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Poland;Slovakia;South Korea;Spain;Switzerland;Taiwan;Turkey (Türkiye);United Kingdom;United States;Vietnam
      2022   -   NCT05222412   -
      2021   Phase 3   NCT04817618   Argentina;Belgium;Brazil;Canada;China;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Turkey (Türkiye);United Kingdom;United States
Iptacopan hydrochloride
   Novartis Pharma AG
      2023   Phase 3   EUCTR2020-004589-21-SK   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      2023   Phase 3   EUCTR2018-004253-24-NL   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2018-004253-24-GR   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004589-21-DE   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
Irbesartan
   Melbourne Health
      2002   Phase 2/Phase 3   NCT00106561   Australia
Jinshuibao
   Jemincare
      2020   Phase 4   NCT04349683   -
   Shanghai Sixth People's Hospital
      2020   Phase 4   ChiCTR2000031731   China
KP104
   Kira Pharmacenticals (US), LLC.
      2025   Phase 2   NCT05517980   -
L-arginine
   Regional Hospital Holstebro
      2006   Phase 1   NCT00345137   -
Lamivudine
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1995   Phase 2   NCT00001457   United States
Lansoprazole, amoxicillin, clarithromycin
   Istanbul University
      2006   -   NCT00983034   Turkey
Leflunomide
   RenJi Hospital
      2010   -   NCT01172002   China
Leflunomide 20 MG+prednisone 0.5MG/KG/D
   Shenzhen Second People's Hospital
      2019   Phase 4   NCT04020328   China
Lisinopril
   Monia Lorini
      2016   Phase 2   NCT02682459   Italy
Lisinopril actavis - 10 MG compresse 10 compresse IN blister AL/PVC
   AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII
      2015   Phase 2   EUCTR2015-003884-12-IT   Italy
LJP 394
   La Jolla Pharmaceutical Company
      2001   Phase 3   NCT00035308   Austria;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
LNP023
   Maruyama Hideki
      2022   Phase 3   JPRN-jRCT2041220097   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;UK;US
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2017-000889-29-ES   France;Germany;Italy;Spain;United Kingdom;United States
   Novartis Pharma AG
      2023   Phase 3   EUCTR2020-004589-21-SK   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004589-21-DE   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Pharmaceuticals
      2019   Phase 3   NCT03955445   Argentina;Brazil;Canada;China;Czechia;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Turkey (Türkiye);United Kingdom;United States
      2019   Phase 2   NCT03832114   France;Germany;Italy;Spain;United Kingdom;United States
LNP023 hydrochloride
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2017-000889-29-IT   France;Germany;Italy;Spain;United Kingdom;United States
   Novartis Pharma AG
      2019   Phase 2   EUCTR2017-000889-29-FR   France;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2017-000889-29-DE   France;Germany;Italy;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000889-29-GB   France;Germany;Italy;Spain;United Kingdom;United States
LNP023 hydrochloride salt
   Novartis Farmacéutica S.A.
      -   Phase 3   EUCTR2020-004589-21-ES   Argentina;Belgium;Brazil;Canada;China;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2018-004253-24-ES   France;Germany;Italy;Spain;United Kingdom;United States
   Novartis Pharma AG
      2023   Phase 3   EUCTR2018-004253-24-NL   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Türkiye;United Kingdom;United States
      2023   Phase 3   EUCTR2018-004253-24-CZ   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2018-004253-24-GR   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004589-21-NL   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004589-21-GR   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004589-21-FR   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004589-21-CZ   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004253-24-IT   Czech Republic;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004253-24-GB   France;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004253-24-FR   Czech Republic;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2020-004589-21-BE   Argentina;Belgium;Brazil;Canada;China;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2018-004253-24-DE   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Türkiye;United Kingdom;United States
Losartan
   Chinese PLA General Hospital
      2013   -   ChiCTR-TRC-13003612   China
   Seoul National University Hospital
      2014   Phase 3   NCT02232776   Korea, Republic of
   Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100047132   China
   Shuguang Hospital affillated with Shanghai University of TCM
      2020   Phase 0   ChiCTR2000037166   China
Losartan group
   Ewha Womans University
      2018   Phase 3   NCT03357653   -
Mabthera
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 2   EUCTR2018-003437-15-FR   France
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2013   -   EUCTR2011-000221-68-FR   France
Mabthera*EV 1FL 50ML 500MG
   AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
      2012   -   EUCTR2011-006115-59-IT   Italy
Medrol*10CPR DIV 4MG
   AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
      2012   -   EUCTR2011-006115-59-IT   Italy
Menveo
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States
Menveo - polv.E soluz.PER soluz. iniett.-USO intramuscolare-comp. coniug.liofilizz.mena:flac.(vetro) comp. goniug.liqui.mencwy:flac.(vetro)-1 flac+1flac
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2017-000889-29-IT   France;Germany;Italy;Spain;United Kingdom;United States
Menveo – polvere E soluzione PER soluzione iniettabile
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004589-21-IT   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
Methotrexate
   Children's Hospital Affiliated to Chongqing Medical University
      2020   -   ChiCTR2000034214   China
   The First Affiliated Hospital of the Air Force Military Medical University of the People's Liberation Army of China
      2024   -   ChiCTR2400091406   china
Methylprednisolon
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany
Methylprednisolone
   Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
      2012   Phase 3   NCT03018535   Italy
   Children's Hospital Affiliated to Chongqing Medical University
      2020   -   ChiCTR2000034214   China
   ISTITUTO GIANNINA GASLINI
      2008   -   EUCTR2007-007793-29-IT   Italy
   Oulu University Hospital
      2000   Phase 4   NCT00425724   Finland
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany
   Sun Yat-sen University
      2014   Phase 2   NCT02160132   China
   The George Institute
      2012   -   NCT01560052   Australia;Canada;China;Hong Kong;India;Malaysia
Methylprednisolone pulse
   Peking University First Hospital
      2016   Phase 2/Phase 3   NCT02647255   China
Mezagitamab
   Nishizawa Atsushi
      2022   Phase 1   JPRN-jRCT2011220009   Australia;China;Hungary;Italy;Japan;Singapore;South Korea;Spain;Taiwan;UK;USA
   Takeda
      2022   Phase 1   NCT05174221   Australia;Belgium;China;Hungary;Italy;Japan;Serbia;Singapore;South Korea;Spain;Taiwan;United Kingdom;United States
MOR202
   HI-Bio, A Biogen Company
      2021   Phase 2   NCT04733040   Georgia;Germany;Greece;Korea, Republic of;Russian Federation;Taiwan;United Kingdom
      2019   Phase 1/Phase 2   NCT04145440   Australia;Belgium;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States
MSC treatment
   Universidad de los Andes, Chile
      2019   Phase 2   NCT03917797   Chile
Mycophenolate mofetil
   Bristol-Myers Squibb
      2007   Phase 2/Phase 3   NCT00430677   Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2014   Phase 3   EUCTR2012-000714-11-ES   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;India;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2013   Phase 3   EUCTR2012-000714-11-RO   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;India;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2013   Phase 3   EUCTR2012-000714-11-IT   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;India;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2013   Phase 3   EUCTR2012-000714-11-CZ   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2008   Phase 2;Phase 3   EUCTR2005-004575-37-GB   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-FR   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-BE   Belgium;France;United Kingdom
   Children's Hospital Affiliated to Chongqing Medical University
      2020   -   ChiCTR2000034214   China
   Frédéric A. Houssiau, MD, PhD
      2001   Phase 3   NCT00204022   Belgium
   IRCCS Istituto Giannina Gaslini
      -   Phase 2   EUCTR2018-001042-33-IT   Italy
   Nephrology Department of West China Hospital
      2010   -   ChiCTR-TRC-10001052   China
   Radboud University
      2002   Phase 2/Phase 3   NCT00135967   Netherlands
   The First Affiliated Hospital of the Air Force Military Medical University of the People's Liberation Army of China
      2024   -   ChiCTR2400091406   china
   University of Washington
      2006   Phase 2   NCT00446459   United States
      2006   Phase 2   NCT00446251   United States
Mycophenolate mofetil (MMF) and SOC
   Christian Medical College, Vellore, India
      2025   Phase 4   NCT06676384   India
Mycophenolate mofetil, LOW dose steroid
   Kyungpook National University Hospital
      2011   Phase 3   NCT01282073   South Korea
Mycophenolate sodium
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Mycophenolic acid
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Mycophenolic sodium
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Mycophenylate mofetil
   Imperial College Healthcare NHS trust
      2008   Phase 4   EUCTR2008-001009-41-GB   United Kingdom
Mycopheylate mofetil
   Imperial College Healthcare NHS trust
      2008   Phase 4   EUCTR2008-001009-41-GB   United Kingdom
Myfenax
   Bristol-Myers Squibb International Corporation
      2014   Phase 3   EUCTR2012-000714-11-ES   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;India;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2013   Phase 3   EUCTR2012-000714-11-RO   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;India;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2013   Phase 3   EUCTR2012-000714-11-CZ   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
   IRCCS Istituto Giannina Gaslini
      -   Phase 2   EUCTR2018-001042-33-IT   Italy
Myfortic 180MG tablets
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Myfortic 360MG tablets
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Narsoplimab
   Omeros Corporation
      2016   Phase 2   NCT02682407   Hong Kong;United States
Nefecon
   Chinese PLA General Hospital
      2025   -   NCT07585981   China
Nimenrix
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004589-21-IT   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
NM8074
   NovelMed Therapeutics
      2027   Phase 1/Phase 2   NCT05647811   -
NON-steroidal mineralocorticoid receptor antagonist and SOC
   Christian Medical College, Vellore, India
      2025   Phase 4   NCT06676384   India
Obinutuzumab
   Mayo Clinic
      2024   Phase 2   NCT06295770   United States
Ofatumumab
   IRCCS Istituto Giannina Gaslini
      -   Phase 2   EUCTR2018-001042-33-IT   Italy
Olmesartan medoxomil
   Daiichi Sankyo Co., Ltd.
      2005   Phase 2   NCT00914524   Japan
Omega-3 fatty acids
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1997   Phase 2   NCT00004448   United States
OMS721
   Omeros Corporation
      2016   Phase 2   NCT02682407   Hong Kong;United States
OMS906 study drug
   Omeros Corporation
      2024   Phase 2   NCT06209736   Lithuania;New Zealand;Poland;Tunisia;Turkey (Türkiye);United Kingdom
Oral cyclosporine
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2010   Phase 2   NCT00977977   United States
Oral prednisolone and SOC
   Christian Medical College, Vellore, India
      2025   Phase 4   NCT06676384   India
Orencia
   Bristol-Myers Squibb International Corporation
      2014   Phase 3   EUCTR2012-000714-11-ES   Argentina;Australia;Brazil;Canada;Chile;China;Colombia;Czech Republic;Hong Kong;India;Italy;Japan;Korea, Republic of;Mexico;Peru;Romania;Russian Federation;Spain;Taiwan;United States
      2008   Phase 2;Phase 3   EUCTR2005-004575-37-GB   Belgium;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2005-004575-37-BE   Belgium;France;United Kingdom
Pegcetacoplan
   APELLIS PHARMACEUTCIALS, INC.
      2022   Phase 3   EUCTR2020-003767-25-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Apellis Pharmaceuticals, Inc.
      2023   Phase 3   NCT05809531   Argentina;Australia;Belgium;Brazil;Czechia;France;Israel;Italy;Japan;Netherlands;South Korea;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   NCT05067127   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;France;Germany;Israel;Italy;Japan;Netherlands;Poland;South Korea;Spain;Switzerland;United Kingdom;United States
      2021   -   NCT04729062   United States
      2021   Phase 2   NCT04572854   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-NL   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-FR   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-AT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2020   Phase 2   EUCTR2020-002637-15-GB   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2022-002833-33-FR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2022-002833-33-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2020-003767-25-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
   Mizuno Masashi
      2023   Phase 3   JPRN-jRCT2041230022   Argentina;Austrarlia;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Israel;Italy;Japan;Korea;Netherland;Poland;Spain;Switzeland;UK;US
Pentoxifylline
   National Taiwan University Hospital
      2006   Phase 3   NCT00354198   Taiwan
      2000   -   NCT00154661   Taiwan
Pioglitazone
   Assistance Publique - Hôpitaux de Paris
      2023   Phase 3   NCT05946564   France
Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Pneumococcal polysaccharide serotype 11 2.2 µG
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Pneumococcal polysaccharide vaccine solution FOR injection IN A vial
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Pneumovax
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2017-000889-29-IT   France;Germany;Italy;Spain;United Kingdom;United States
Potassium
   Chinese PLA General Hospital
      2013   -   ChiCTR-TRC-13003612   China
   Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100047132   China
   Shuguang Hospital affillated with Shanghai University of TCM
      2020   Phase 0   ChiCTR2000037166   China
Potassium citrate
   European Georges Pompidou Hospital
      2015   -   NCT03836144   France
Prednisolon
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany
Prednisolon 5 MG, tabletten
   Radboudumc, Amalia Children’s Hospital, Department of Pediatrics
      -   Phase 4   EUCTR2016-002430-76-BE   Belgium;Germany;Netherlands
Prednisolon mylan 20 MG
   Radboudumc, Amalia Children’s Hospital, Department of Pediatrics
      -   Phase 4   EUCTR2016-002430-76-BE   Belgium;Germany;Netherlands
Prednisolone
   Aarhus University hospital
      2017   Phase 4   EUCTR2017-001206-16-DK   Denmark
   Bristol-Myers Squibb
      2007   Phase 2/Phase 3   NCT00430677   Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States
   Imperial College NHS trust
      2009   Phase 4   EUCTR2009-014292-52-GB   United Kingdom
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany
   Radboudumc, Amalia Children’s Hospital, Department of Pediatrics
      -   Phase 4   EUCTR2016-002430-76-BE   Belgium;Germany;Netherlands
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Prednisolone acetate
   Radboudumc, Amalia Children’s Hospital, Department of Pediatrics
      2019   Phase 3   EUCTR2016-002430-76-DE   Belgium;Germany;Netherlands
Prednisolone and chlorambucil
   Hospital Authority, Hong Kong
      2003   Phase 3   NCT00404833   China
Prednisolone and mycophenolate mofetil
   Hospital Authority, Hong Kong
      2005   Phase 3   NCT00404794   China
      2003   Phase 3   NCT00404833   China
Prednisolone and tacrolimus
   Hospital Authority, Hong Kong
      2005   Phase 3   NCT00404794   China
Prednisolone plus cyclophosphamide
   Air Force Military Medical University, China
      2024   Phase 3   NCT05510323   China
Prednisolone solution 5MG/ML
   Radboudumc, Amalia Children’s Hospital, Department of Pediatrics
      2016   Phase 4   EUCTR2016-002430-76-NL   Belgium;Germany;Netherlands
Prednisone
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 2   EUCTR2018-003437-15-FR   France
   Bristol-Myers Squibb
      2007   Phase 2/Phase 3   NCT00430677   Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1997   Phase 2   NCT00004448   United States
   Oulu University Hospital
      2000   Phase 4   NCT00425724   Finland
   Peking University
      2006   -   NCT00378443   -
Prednisone 0,5 MG/KG orally ON alternate days
   Radboud University
      2002   Phase 2/Phase 3   NCT00135967   Netherlands
Prevenar 13 - 0.5 ML sospensione iniettabile - USO intramuscolare - flaconcino monodose (0,5 ML vetro tipo I) - 1 flaconcino monodose
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States
Prevenar 13 suspension FOR injection
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Probiotics combined with enteric-coated budesonide capsule
   Gang Xu
      2024   Phase 4   NCT06528015   China
Probucol
   Guangdong General Hospital
      2007   Phase 4   NCT00426348   China
Ramipril
   Sanofi
      2004   Phase 3   NCT00437463   Hong Kong
Ramipril or losartan
   University Magna Graecia
      1997   Phase 4   NCT01115426   Italy
RD06-05 cart cell injection
   Nanjing Bioheng Biotech Co., Ltd.
      2025   Early Phase 1   NCT07203404   China
Remicade
   Department of Rheumatology, Internal Medicine III, Medical University of Vienna
      2006   -   EUCTR2005-004067-30-NL   Austria;Germany;Netherlands
      2006   -   EUCTR2005-004067-30-DE   Austria;Germany;Netherlands
      2006   -   EUCTR2005-004067-30-AT   Austria;Germany;Netherlands
Renin-angiotensin sytem blockers
   Fondazione Schena
      2023   Phase 4   NCT04662723   Italy
Rilzabrutinib
   Sanofi
      2024   Phase 2   NCT06500702   Argentina;Australia;Brazil;Canada;Chile;China;Czechia;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Slovakia;Spain;Taiwan;Turkey (Türkiye);United Kingdom;United States
Rituximab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 2   EUCTR2018-003437-15-FR   France
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2013   -   EUCTR2011-000221-68-FR   France
   Akihito Tanaka
      2023   Phase 3   JPRN-jRCT2041230037   -
   Alentis Therapeutics AG
      2023   Phase 2   NCT06047171   Czechia;Denmark;France;Germany;Italy;Spain;Sweden;Switzerland;Turkey (Türkiye);United Kingdom
   Assiut University
      2017   Phase 3   NCT03180723   -
   Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
      2012   Phase 3   NCT03018535   Italy
   Cambridge University Hospitals NHS Foundation Trust
      2019   Phase 3   EUCTR2018-004611-50-GB   United Kingdom
   Children's Hospital Affiliated to Chongqing Medical University
      2023   -   ChiCTR2300067726   China
      2020   -   ChiCTR2000034214   China
   Department of Cardiorenal Medicine, Yokohama City University School of Medicine
      2011   Phase 3   JPRN-UMIN000006080   Japan
   Mayo Clinic
      2014   Phase 2   NCT02197767   United States
      2005   Phase 1   NCT00275613   United States
   Pediatric Hospital Affiliated to Fudan University
      2021   Phase 4   ChiCTR2100050955   China
   Peking University First Hospital
      2023   -   ChiCTR2500102928   China
   Shoichi Maruyama MD PhD
      2023   Phase 3   NCT05914155   Japan
   University of Washington
      2006   Phase 2   NCT00446251   United States
Rituximab infusion
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2010   Phase 2   NCT00977977   United States
Saquinavir
   OSPEDALE POLICLINICO S. MATTEO
      2009   -   EUCTR2009-013484-19-IT   Italy
SGB-9768
   Suzhou Sanegene Bio Inc.
      2025   Phase 2   NCT06786338   China
Shenyankangfu tablets
   Chinese PLA General Hospital
      2013   -   ChiCTR-TRC-13003612   China
Shenyankangfu tablets and losartan potassium 100MG
   Chinese PLA General Hospital
      2014   Phase 4   NCT02063100   China
Shenyankangfu tablets and losartan potassium 50MG
   Chinese PLA General Hospital
      2014   Phase 4   NCT02063100   China
Simulect
   CHU Saint-Etienne
      2010   Phase 4   EUCTR2009-018189-36-FR   France;Spain
   Centre Hospitalier Universitaire de Saint Etienne
      2011   Phase 4   NCT02523768   France
Simvastatin
   Depertment of Allergy and Rheumatology, University of Tokyo
      2002   Phase 2   JPRN-C000000361   Japan
Sirolimus
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2002   Phase 2   NCT00050713   United States
Sirolimus (study drug)+ACE inhibitor + statin
   Josep m Cruzado
      2006   Phase 2   NCT00396721   Spain
Sodium-glucose cotransporter 2 inhibitor
   Fondazione Schena
      2023   Phase 4   NCT04662723   Italy
Soliris
   IRCCS- Mario Negri Institute
      2014   Phase 2   EUCTR2013-003826-10-IT   Italy
Sparsentan
   University of Leicester
      2020   Phase 2   NCT04663204   United Kingdom
Spironolactone
   Melbourne Health
      2002   Phase 2/Phase 3   NCT00106561   Australia
SQ fludarabine
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      1998   Phase 1   NCT00001676   United States
Standard OF care
   Universidad de los Andes, Chile
      2019   Phase 2   NCT03917797   Chile
Sulfamethoxazole
   The First Affiliated Hospital of the Air Force Military Medical University of the People's Liberation Army of China
      2024   -   ChiCTR2400091406   china
Supportive therapy
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany
Tacrolimus
   Imperial College NHS trust
      2009   Phase 4   EUCTR2009-014292-52-GB   United Kingdom
Tacrolimus &entecavir
   Guangdong General Hospital
      2017   Phase 4   NCT03062813   China
Tacrolimus and mycophenolate mofetil
   Imperial College Healthcare NHS Trust
      2009   Phase 4   NCT00843856   United Kingdom
Telitacicept
   ADARx Pharmaceuticals, Inc.
      2026   Phase 2   NCT07522099   China
   Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
      2026   Phase 4   ChiCTR2600122522   China
Telitacicept 160MG
   Peking University First Hospital
      2025   Phase 2   NCT07111338   China
Tetract-HIB - 1 siringa precaricata 0.5 ML
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States
THE 0.5 ML dose OF vaccine contains 25 micrograms OF each OF THE following 23 pneumococcal polysaccharide
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Tocilizumab
   Department of Cardiorenal Medicine, Yokohama City University School of Medicine
      2011   Phase 3   JPRN-UMIN000006080   Japan
TP10
   University of Iowa
      2014   Phase 1   NCT02302755   United States
Urbason*IM EV 1F 250MG+1F 5ML
   AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
      2012   -   EUCTR2011-006115-59-IT   Italy
Urine sample
   Centre Hospitalier Universitaire de Besancon
      2023   -   NCT05791162   France
Vaccino contro IL memingococco DI gruppo B
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004589-21-IT   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
Vaccino haemophilus influenzae B coniugato CON tossoidetetanico
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004589-21-IT   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States
Valsartan
   Columbia University
      2009   Phase 4   NCT01129557   United States
   Guangdong General Hospital
      2007   Phase 4   NCT00426348   China
   the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
      2017   -   ChiCTR-INR-17011060   China
   the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100053690   China
Valsartan capsule
   The First Affiliated Hospital of Dalian Medical University
      2020   Phase 4   NCT04263922   China
Zigakibart
   Novartis Pharmaceuticals
      2025   Phase 3   NCT06858319   Argentina;Australia;Malaysia;South Korea;United States
Zinc chloride
   Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate Shool of Medical Sciences
      2012   -   JPRN-UMIN000009157   Japan